Seres Therapeutics’ (MCRB) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a report released on Wednesday,Benzinga reports. The brokerage currently has a $1.25 price target on the biotechnology company’s stock.

A number of other analysts also recently issued reports on the company. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 price objective on shares of Seres Therapeutics in a report on Friday, September 13th. Finally, JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Seres Therapeutics presently has an average rating of “Hold” and a consensus target price of $5.08.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $0.55 on Wednesday. The stock has a market capitalization of $93.56 million, a PE ratio of -2.39 and a beta of 2.06. Seres Therapeutics has a one year low of $0.54 and a one year high of $2.05. The business’s 50 day simple moving average is $0.85 and its 200 day simple moving average is $0.92.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.08. During the same period in the prior year, the company posted $0.36 earnings per share. As a group, research analysts expect that Seres Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Seres Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Seres Therapeutics in the first quarter worth $39,000. Providence Wealth Advisors LLC lifted its position in Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 25,250 shares during the period. Point72 DIFC Ltd purchased a new position in Seres Therapeutics during the second quarter valued at $64,000. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics in the 1st quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Seres Therapeutics in the 2nd quarter worth approximately $92,000. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.